» Articles » PMID: 25384486

Sinusitis and Pneumonia Hospitalization After Introduction of Pneumococcal Conjugate Vaccine

Overview
Journal Pediatrics
Specialty Pediatrics
Date 2014 Nov 12
PMID 25384486
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Objective: Streptococcus pneumoniae is a major cause of pneumonia and sinusitis. Pneumonia kills >1 million children annually, and sinusitis is a potentially serious pediatric disease that increases the risk of orbital and intracranial complications. Although pneumococcal conjugate vaccine (PCV) is effective against invasive pneumococcal disease, its effectiveness against pneumonia is less consistent, and its effect on sinusitis is not known. We compared hospitalization rates due to sinusitis, pneumonia, and empyema before and after sequential introduction of PCV7 and PCV13.

Method: All children 0 to <18 years old hospitalized for sinusitis, pneumonia, or empyema in Stockholm County, Sweden, from 2003 to 2012 were included in a population-based study of hospital registry data on hospitalizations due to sinusitis, pneumonia, or empyema. Trend analysis, incidence rates, and rate ratios (RRs) were calculated comparing July 2003 to June 2007 with July 2008 to June 2012, excluding the year of PCV7 introduction.

Results: Hospitalizations for sinusitis decreased significantly in children aged 0 to <2 years, from 70 to 24 cases per 100 000 population (RR = 0.34, P < .001). Hospitalizations for pneumonia decreased significantly in children aged 0 to <2 years, from 450 to 366 per 100 000 population (RR = 0.81, P < .001) and in those aged 2 to <5 years from 250 to 212 per 100 000 population (RR = 0.85, P = .002). Hospitalization for empyema increased nonsignificantly. Trend analyses showed increasing hospitalization for pneumonia in children 0 to <2 years before intervention and confirmed a decrease in hospitalizations for sinusitis and pneumonia in children aged 0 to <5 years after intervention.

Conclusions: PCV7 and PCV13 vaccination led to a 66% lower risk of hospitalization for sinusitis and 19% lower risk of hospitalization for pneumonia in children aged 0 to <2 years, in a comparison of 4 years before and 4 years after vaccine introduction.

Citing Articles

Sex-differences in incidence of hospitalizations and in hospital mortality of community-acquired pneumonia among children in Spain: a population-based study.

de-Miguel-Diez J, Lopez-de-Andres A, Hernandez-Barrera V, de-Miguel-Yanes J, Carabantes-Alarcon D, Ji Z Eur J Pediatr. 2022; 181(7):2705-2713.

PMID: 35469030 PMC: 9192385. DOI: 10.1007/s00431-022-04478-9.


Decrease of Pneumococcal Community-Acquired Pneumonia Hospitalization and Associated Complications in Children after the Implementation of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) in Taiwan.

Shen C, Chen J, Su C, Lin W, Hsieh M, Liu C Vaccines (Basel). 2021; 9(9).

PMID: 34579280 PMC: 8471531. DOI: 10.3390/vaccines9091043.


Etiology of Clinical Community-Acquired Pneumonia in Swedish Children Aged 1-59 Months with High Pneumococcal Vaccine Coverage-The TREND Study.

Eklundh A, Rhedin S, Ryd-Rinder M, Andersson M, Gantelius J, Gaudenzi G Vaccines (Basel). 2021; 9(4).

PMID: 33919904 PMC: 8070909. DOI: 10.3390/vaccines9040384.


Pneumonia in Infancy and Risk for Asthma: The Role of Familial Confounding and Pneumococcal Vaccination.

Rhedin S, Lundholm C, Caffrey Osvald E, Almqvist C Chest. 2021; 160(2):422-431.

PMID: 33727032 PMC: 8411448. DOI: 10.1016/j.chest.2021.03.006.


Hospitalizations for lower respiratory tract infections in children in relation to the sequential use of three pneumococcal vaccines in Quebec.

Zhou Z, Gilca R, Deceuninck G, Boucher F, De Wals P Can J Public Health. 2020; 111(6):1041-1048.

PMID: 32529553 PMC: 7728929. DOI: 10.17269/s41997-020-00329-y.